Apellis Pharmaceuticals Inc
APLS
Company Profile
Business description
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Contact
100 Fifth Avenue
WalthamMA02451
USAT: +1 617 977-5700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
710
Stocks News & Analysis
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
stocks
Our view on oil prices after Maduro is deposed
We’ve revisited our oil price assumptions after the news from Venezuela.
stocks
Nvidia: Full steam ahead with an impressive array of announcements at CES 2026
Our view of Nvidia at the current share price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,030.10 | 9.40 | -0.10% |
| CAC 40 | 8,237.43 | 25.93 | 0.32% |
| DAX 40 | 24,892.20 | 23.51 | 0.09% |
| Dow JONES (US) | 49,462.08 | 484.90 | 0.99% |
| FTSE 100 | 10,122.73 | 118.16 | 1.18% |
| HKSE | 26,569.15 | 141.30 | -0.53% |
| NASDAQ | 23,547.17 | 151.35 | 0.65% |
| Nikkei 225 | 52,321.25 | 196.83 | -0.37% |
| NZX 50 Index | 13,713.62 | 50.04 | 0.37% |
| S&P 500 | 6,944.82 | 42.77 | 0.62% |
| S&P/ASX 200 | 8,711.50 | 12.00 | -0.14% |
| SSE Composite Index | 4,081.82 | 1.84 | -0.05% |